$0.38
0.02 (+5.92%)
CytRx Corp (NASDAQ:CYTR)
CAPS Rating:
A biopharmaceutical research and development company engaged in developing human therapeutic products based primarily upon its small molecule molecular chaperone co-induction technology.
RSS Headlines
Fool UK